Cassava Sciences Inc

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cassava Sciences advances Phase III trial with strong financial footing

Cassava Sciences is progressing well with Phase III trial milestones and financial stability, poised to announce critical trial results by year-end.
While facing challenges in data accuracy and increased expenses, the company's proactive approach and strategic planning present significant growth opportunities.
By focusing on innovation and market transformation, Cassava Sciences is positioned to redefine Alzheimer's disease diagnosis and treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

NEW YORK, NY / ACCESSWIRE / November 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.

SAVA ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Cassava Sciences, Inc. Shareholders Who Lost Money

NEW YORK CITY, NY / ACCESSWIRE / November 25, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA). Investors who purchased Cassava securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAVA.

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cassava Sciences, Inc. (SAVA) and Encourages Stockholders to Learn More About the Investigation

Cassava Sciences (SAVA), the Austin-based biotech firm specializing in neurodegenerative diseases, suffered a major blow on Monday when its stock plunged 85%. The sharp drop came after the company announced that its Phase 3 clinical trial for simufilam, an experimental Alzheimer's treatment, failed to meet its primary endpoints.

Cassava Sciences plummets 85% after Alzheimer's drug trial failure

Cassava Sciences SAVA stock is falling Monday after the company shared an update on its Phase 3 trial for a treatment for Alzheimer's disease that has been widely followed by the market.

'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update

Cassava Sciences stock plummeted Monday after the company's Alzheimer's treatment failed in Phase 3 testing. The post Cassava Sciences Plummets 84% After Embattled Alzheimer's Drug Flops appeared first on Investor's Business Daily.

Cassava Sciences Plummets 84% After Embattled Alzheimer's Drug Flops

Cassava Sciences (SAVA) shares are plunging in premarket trading and are losing most of their value after the biotech firm said its experimental Simufilam drug—aimed at treating Alzheimer's disease (AD)—failed to show a “significant reduction in cognitive or functional decline” during the Phase 3 trial of the treatment.

Cassava Stock Plunges as Alzheimer's Drug Fails Late-Stage Study

Cassava Sciences Inc.  SAVA stock plunged Monday after the company released topline data from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate Alzheimer's disease.

Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies

The biotech says it will discontinue a second trial but will still offer full analyses of the data.

Cassava Sciences' stock craters after Alzheimer's disease trial fails to meet its goals

Biohaven Pharmaceutical Hld

U.S. stock futures were higher this morning, with the Dow futures gaining more than 300 points on Monday.

Cassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's disease in the ReThink-ALZ Phase 3 study

Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints

AUSTIN, Texas, Nov. 24, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer's disease, today announced it will hold a conference call and webcast on Monday, November 25th at 8:00 a.m. Eastern Time.

Cassava Sciences to Hold Corporate Update on November 25th

Ms. Nassif brings an extensive track record of successfully developing commercial strategies for multiple FDA-approved drugs

Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer

Here is how Cassava Sciences, Inc. (SAVA) and biote Corp. (BTMD) have performed compared to their sector so far this year.

Is Cassava Sciences (SAVA) Outperforming Other Medical Stocks This Year?

Cassava Sciences (SAVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Cassava Sciences (SAVA) a New Buy Stock

Panax ginseng shows the highest effectiveness in treating Alzheimer's because it inhibits nitro-oxidative stress, scavenges peroxynitrite, and reverses part of its damage, leading to sustained cognitive improvements over two years. Anavex's Blarcamesine may slow mild Alzheimer's progression due to its antioxidant capacity, with results from a 96-week trial potentially aiding regulatory approval. Cassava Sciences' Simufilam's effectiveness is limited to one year for mild Alzheimer's, with no residual effects after discontinuation, and mixed results in combined mild and moderate groups.

Anavex, Cassava Sciences, Panax Ginseng, And The Long-Term Treatment Of Alzheimer's Disease

Cassava Sciences, Inc. (NASDAQ:SAVA ) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Rick Barry - President & Chief Executive Officer Eric Schoen - Chief Financial Officer Conference Call Participants Vernon Bernardino - H.C. Wainwright Elemer Piros - Rodman Operator Ladies and gentlemen, welcome to Cassava Sciences Report for the Third Quarter 2024.

Cassava Sciences, Inc. (SAVA) Q3 2024 Earnings Call Transcript

AUSTIN, Texas, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer's disease, today reported financial results for the third quarter ended September 30, 2024.

Cassava Sciences Reports Q3 2024 Financial and Operating Results

AUSTIN, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it will hold a conference call on Thursday, November 7th at 8:30 a.m. Eastern Time.

Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024

Cassava Sciences Inc. NASDAQ: SAVA is a biotech developing treatments for Alzheimer's disease. The company has a lot of controversy over its lead drug, simufilam, which attempts to go further than alleviate symptoms but actually modify the underlying biology of the disease.

Analysts Believe Cassava Sciences Now Has 300% Upside From Here

Last month, Cassava Sciences Inc. SAVA agreed to pay over $40 million to resolve SEC charges over misleading statements related to a Phase 2 trial of the company's controversial Alzheimer's drug, simufilam.

What's Going On With Alzheimer's-Focused Cassava Sciences On Tuesday?

Casava stock falls as the company agrees to pay a cumulative fine exceeding $40 million to settle misleading claims charges brought against it by the SEC.

SAVA Stock Down on Settling Misleading Alzheimer's Study Data Claims

The biotech is paying $40 million not to acquire a drug or fund a development program, but to satisfy a regulator. The money is going toward a settlement with the Securities and Exchange Commission.

Why Cassava Sciences Stock Dived by Almost 11% Today

Cassava Sciences (SAVA) shares dropped more than 11% after the company agreed to a $40 million settlement with the Securities and Exchange Commission (SEC) over charges that it manipulated clinical trial data related to its Alzheimer's disease drug.

Cassava's Stock Drops After It Agrees to Pay $40M to Settle SEC Alzheimer's Claims

Alzheimer's drug developer Cassava Sciences Inc SAVA, its founder Remi Barbier, and former Senior VP of Neuroscience Lindsay Burns have agreed to pay over $40 million to resolve SEC charges over misleading statements related to a Phase 2 trial of the company's controversial Alzheimer's drug, simufilam.

SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial Data, Company And Former Execs Agree To Pay Penalty

Shares of Cassava Sciences Inc. dropped more than 10% in the extended session Thursday after announcing a settlement with U.S. securities regulators, who had charged the pharma company and two former executives for “misleading claims” about an Alzheimer's clinical trial.

News for Cassava Sciences Inc Stock (SAVA)